PURCHASE, N.Y., July 22 Nutrition 21, Inc.(Nasdaq: NXXI), a developer and marketer of nutritional supplements that helpconsumers manage blood sugar levels, improve cardiovascular health, enhancememory and address chronic joint pain, today announced its agreement withWalgreens to supply three new chromium picolinate products for the FinestNatural(R) retail brand and one product for the Walgreens Gold Seal PrivateLabel. These products are anticipated to be available late this summer orearly fall.
Walgreens, one of the largest retailers in the United States, has 6,300stores in 49 states. "Walgreens commitment is a major milestone in our move toexpand our retail nutrition supplement business by working with industry-moving retailers to meet the growing needs of health-conscious consumers,"said Michael Fink, co-Chief Operating Officer of Nutrition 21. "It alsoreflects the growing appreciation by retailers of Nutrition 21's continuingcommitment to develop and market proprietary and clinically substantiatednutraceuticals that address significant health care concerns. We anticipatebeginning to receive revenues from these new products during the quarterending September 30, 2008."
About Nutrition 21
Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is anutritional bioscience company and the maker of chromium picolinate-based andomega-3 fish oil-based supplements with health benefits substantiated byclinical research. Nutrition 21 holds more than 30 patents for nutritionproducts and uses. Nutrition 21's portfolio of health and wellness brandsinclude: Chromax(R), Core4Life Advanced Memory Formula(TM), DiabetesEssentials(TM), Iceland Health(R) Maximum Strength Omega-3 and IcelandHealth(R) Joint Relief. The company also manufactures private labelsupplements and ingredients for third parties. Nutrition 21 distributes itsproducts nationally through more than 29,000 major food, drug and super centerretailers as well as internationally. For more information please visithttp://www.nutrition21.com.
Safe Harbor Provision
This press release may contain certain forward-looking statements. Thewords "believe," "expect," "anticipate" and other similar expressionsgenerally identify forward-looking statements. Readers are cautioned not toplace undue reliance on these forward-looking statements, which speak only asof their dates. These forward-looking statements are based largely on theCompany's current expectations and are subject to a number of risks anduncertainties, including without limitation: the effect of the expiration ofpatents; regulatory issues; uncertainty in the outcomes of clinical trials;changes in external market factors; changes in the Company's business orgrowth strategy or an inability to execute its strategy due to changes in itsindustry or the economy generally; the emergence of new or growingcompetitors; various other competitive factors; and other risks anduncertainties indicated from time to time in the Company's filings with theSecurities and Exchange Commission, including its Form 10-K/A for the yearended June 30, 2007. Actual results could differ materially from the resultsreferred to in the forward-looking statements. In light of these risks anduncertainties, there can be no assurance that the results referred to in theforward-looking statements contained in this press release will in fact occur.Additionally, the Company makes no commitment to disclose any revisions toforward-looking statements, or any facts, events or circumstances after thedate hereof that may bear upon forward-looking statements.
CONTACT: Joe DiazLytham Partners, LLC (602) 889-9700
SOURCE Nutrition 21, Inc.